428 related articles for article (PubMed ID: 30451293)
21. POT1 loss-of-function variants predispose to familial melanoma.
Robles-Espinoza CD; Harland M; Ramsay AJ; Aoude LG; Quesada V; Ding Z; Pooley KA; Pritchard AL; Tiffen JC; Petljak M; Palmer JM; Symmons J; Johansson P; Stark MS; Gartside MG; Snowden H; Montgomery GW; Martin NG; Liu JZ; Choi J; Makowski M; Brown KM; Dunning AM; Keane TM; López-Otín C; Gruis NA; Hayward NK; Bishop DT; Newton-Bishop JA; Adams DJ
Nat Genet; 2014 May; 46(5):478-481. PubMed ID: 24686849
[TBL] [Abstract][Full Text] [Related]
22. Germline Variants in the POT1-Gene in High-Risk Melanoma Patients in Austria.
Müller C; Krunic M; Wendt J; von Haeseler A; Okamoto I
G3 (Bethesda); 2018 May; 8(5):1475-1480. PubMed ID: 29523635
[TBL] [Abstract][Full Text] [Related]
23.
Shen E; Xiu J; Lopez GY; Bentley R; Jalali A; Heimberger AB; Bainbridge MN; Bondy ML; Walsh KM
J Med Genet; 2020 Oct; 57(10):664-670. PubMed ID: 31937561
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group.
Soufir N; Avril MF; Chompret A; Demenais F; Bombled J; Spatz A; Stoppa-Lyonnet D; Bénard J; Bressac-de Paillerets B
Hum Mol Genet; 1998 Feb; 7(2):209-16. PubMed ID: 9425228
[TBL] [Abstract][Full Text] [Related]
25. Germline CDKN2A mutations among Greek patients with early-onset and multiple primary cutaneous melanoma.
Stratigos AJ; Yang G; Dimisianos R; Nicolaou V; Stefanaki I; Katsambas AD; Tsao H
J Invest Dermatol; 2006 Feb; 126(2):399-401. PubMed ID: 16374456
[TBL] [Abstract][Full Text] [Related]
26. High- and intermediate-risk susceptibility variants in melanoma families from the Mediterranean area: A multicentre cohort from the MelaNostrum Consortium.
Pellegrini C; Cardelli L; Ghiorzo P; Pastorino L; Potrony M; García-Casado Z; Elefanti L; Stefanaki I; Mastrangelo M; Necozione S; Aguilera P; Rodríguez-Hernández A; Di Nardo L; Rocco T; Del Regno L; Badenas C; Carrera C; Malvehy J; Requena C; Bañuls J; Stratigos AJ; Peris K; Menin C; Calista D; Nagore E; Puig S; Landi MT; Fargnoli MC
J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):2498-2508. PubMed ID: 37611275
[TBL] [Abstract][Full Text] [Related]
27. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.
Platz A; Hansson J; Månsson-Brahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganäs M; Ringborg U
J Natl Cancer Inst; 1997 May; 89(10):697-702. PubMed ID: 9168184
[TBL] [Abstract][Full Text] [Related]
28. Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF.
Mangas C; Potrony M; Mainetti C; Bianchi E; Carrozza Merlani P; Mancarella Eberhardt A; Maspoli-Postizzi E; Marazza G; Marcollo-Pini A; Pelloni F; Sessa C; Simona B; Puig-Butillé JA; Badenas C; Puig S
Br J Dermatol; 2016 Nov; 175(5):1030-1037. PubMed ID: 27473757
[TBL] [Abstract][Full Text] [Related]
29. Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma.
Soufir N; Lacapere JJ; Bertrand G; Matichard E; Meziani R; Mirebeau D; Descamps V; Gérard B; Archimbaud A; Ollivaud L; Bouscarat F; Baccard M; Lanternier G; Saïag P; Lebbé C; Basset-Seguin N; Crickx B; Cave H; Grandchamp B
Br J Cancer; 2004 Jan; 90(2):503-9. PubMed ID: 14735200
[TBL] [Abstract][Full Text] [Related]
30. Novel CDKN2A mutation detected in Spanish melanoma pedigree.
de Torre C; Martínez-Escribano J
Exp Dermatol; 2010 Aug; 19(8):e333-5. PubMed ID: 20653773
[TBL] [Abstract][Full Text] [Related]
31. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants.
Puntervoll HE; Yang XR; Vetti HH; Bachmann IM; Avril MF; Benfodda M; Catricalà C; Dalle S; Duval-Modeste AB; Ghiorzo P; Grammatico P; Harland M; Hayward NK; Hu HH; Jouary T; Martin-Denavit T; Ozola A; Palmer JM; Pastorino L; Pjanova D; Soufir N; Steine SJ; Stratigos AJ; Thomas L; Tinat J; Tsao H; Veinalde R; Tucker MA; Bressac-de Paillerets B; Newton-Bishop JA; Goldstein AM; Akslen LA; Molven A
J Med Genet; 2013 Apr; 50(4):264-70. PubMed ID: 23384855
[TBL] [Abstract][Full Text] [Related]
32. Telomere-lengthening germline variants predispose to a syndromic papillary thyroid cancer subtype.
DeBoy EA; Nicosia AM; Liyanarachchi S; Iyer SS; Shah MH; Ringel MD; Brock P; Armanios M
Am J Hum Genet; 2024 Jun; 111(6):1114-1124. PubMed ID: 38688277
[TBL] [Abstract][Full Text] [Related]
33. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411
[TBL] [Abstract][Full Text] [Related]
34. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S
J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638
[TBL] [Abstract][Full Text] [Related]
35. POLE mutations in families predisposed to cutaneous melanoma.
Aoude LG; Heitzer E; Johansson P; Gartside M; Wadt K; Pritchard AL; Palmer JM; Symmons J; Gerdes AM; Montgomery GW; Martin NG; Tomlinson I; Kearsey S; Hayward NK
Fam Cancer; 2015 Dec; 14(4):621-8. PubMed ID: 26251183
[TBL] [Abstract][Full Text] [Related]
36. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
[TBL] [Abstract][Full Text] [Related]
37. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.
Maubec E; Chaudru V; Mohamdi H; Blondel C; Margaritte-Jeannin P; Forget S; Corda E; Boitier F; Dalle S; Vabres P; Perrot JL; Lyonnet DS; Zattara H; Mansard S; Grange F; Leccia MT; Vincent-Fetita L; Martin L; Crickx B; Joly P; Thomas L; ; Bressac-de Paillerets B; Avril MF; Demenais F
J Am Acad Dermatol; 2012 Dec; 67(6):1257-64. PubMed ID: 22841127
[TBL] [Abstract][Full Text] [Related]
38. CDKN2A germline mutations in familial pancreatic cancer.
Bartsch DK; Sina-Frey M; Lang S; Wild A; Gerdes B; Barth P; Kress R; Grützmann R; Colombo-Benkmann M; Ziegler A; Hahn SA; Rothmund M; Rieder H
Ann Surg; 2002 Dec; 236(6):730-7. PubMed ID: 12454511
[TBL] [Abstract][Full Text] [Related]
39. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
[TBL] [Abstract][Full Text] [Related]
40. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.
Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G
Pigment Cell Melanoma Res; 2008 Dec; 21(6):700-9. PubMed ID: 18983535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
